AI assistant
Sending…
IRLAB Therapeutics — Director's Dealing 2023
Mar 7, 2023
3062_iss_2023-03-07_096fc1ac-1204-4663-89af-7a45ecb329c2.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Issuer IRLAB Therapeutics AB
Holder
196804 Daniel Johnsson
Instrument
| Instrument | Aktie SE0012675361 |
|---|---|
| Before the transaction | |
| Shares | 2,690,000 |
| Voting rights | 2,690,000 |
| Transaction | |
| Date | 07/03/2023 |
| Limit for number of shares 5 % | |
| Limit for number of votes | 5 % |
| After the transaction | |
| Quantity |
| Shares | 4,500,000 |
|---|---|
| Directly held voting rights 4,500,000 | |
| Indirectly held voting rights 0 |
Percentage
Directly held shares 8.66 % Directly held voting rights 8.66 % Indirectly held voting rights 0 %
Resulting distribution of total
| holdings | ||
|---|---|---|
| Percentage of voting rights: |
Number of underlying shares: |
|
| Shares | 8.66 % | 4,500,000 |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 Instruments - FITA Ch. 4, section 2, |
||
| first paragraph, line 3 | ||
| - Physically settled | ||
| - Cash settled | ||
| Total | 8.66 % | 4,500,000 |
| Group total holdings | ||
| Voting rights 4,500,000 |
||
| Percentage of voting rights 8.66 | ||
| Published | ||
| 07/03/2023 22:34 | ||
| Contact Name |
||
| Daniel Johnsson Phone +46736876400 Email [email protected] |
||
[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from IRLAB Therapeutics
Proxy Solicitation & Information Statement
2026
May 29
Interim / Quarterly Report
2026
May 6
Interim / Quarterly Report
2026
May 6
Proxy Solicitation & Information Statement
2026
May 5
Proxy Solicitation & Information Statement
2026
May 5
Capital/Financing Update
2026
May 5
Capital/Financing Update
2026
May 5
Annual Report
2026
Apr 29
Annual Report
2026
Apr 29
Board/Management Information
2026
Apr 17